Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Quanterix Yönetim

Yönetim kriter kontrolleri 2/4

Quanterix's CEO'su Masoud Toloue, Apr2022 tarihinde atandı, in görev süresi 2.5 yıldır. in toplam yıllık tazminatı $ 5.44M olup, şirket hissesi ve opsiyonları dahil olmak üzere 11.3% maaş ve 88.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.53% ine doğrudan sahiptir ve bu hisseler $ 2.62M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.5 yıl ve 5.3 yıldır.

Anahtar bilgiler

Masoud Toloue

İcra Kurulu Başkanı

US$5.4m

Toplam tazminat

CEO maaş yüzdesi	11.3%
CEO görev süresi	2.5yrs
CEO sahipliği	0.5%
Yönetim ortalama görev süresi	2.5yrs
Yönetim Kurulu ortalama görev süresi	5.3yrs

Son yönetim güncellemeleri

Recent updates

Quanterix Corporation: Still Struggling To Gain Traction

Aug 26

Take Care Before Jumping Onto Quanterix Corporation (NASDAQ:QTRX) Even Though It's 26% Cheaper

Aug 15

Positive Sentiment Still Eludes Quanterix Corporation (NASDAQ:QTRX) Following 25% Share Price Slump

Jun 27

Quanterix Corporation's (NASDAQ:QTRX) 31% Cheaper Price Remains In Tune With Revenues

Apr 14

Quanterix (NASDAQ:QTRX) Is In A Strong Position To Grow Its Business

Apr 05

Quanterix Corporation (NASDAQ:QTRX) Yearly Results: Here's What Analysts Are Forecasting For This Year

Mar 03

Here's Why We're Not Too Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Situation

Oct 12

CEO Tazminat Analizi

Masoud Toloue'un ücretlendirmesi Quanterix'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$40m
Mar 31 2024	n/a	n/a	-US$36m
Dec 31 2023	US$5m	US$615k	-US$32m
Sep 30 2023	n/a	n/a	-US$39m
Jun 30 2023	n/a	n/a	-US$66m
Mar 31 2023	n/a	n/a	-US$85m
Dec 31 2022	US$3m	US$541k	-US$97m
Sep 30 2022	n/a	n/a	-US$98m
Jun 30 2022	n/a	n/a	-US$79m
Mar 31 2022	n/a	n/a	-US$66m
Dec 31 2021	US$4m	US$279k	-US$58m

Tazminat ve Piyasa: Masoud 'nin toplam tazminatı ($USD 5.44M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.40M ).

Tazminat ve Kazançlar: Masoud şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Masoud Toloue (43 yo)

2.5yrs

Görev süresi

US$5,435,274

Tazminat

Dr. Masoud Toloue, Ph D., serves as Chief Executive Officer, President and Director of Quanterix Corporation since April 25, 2022. He served as Head of Diagnostics Business of Quanterix Corporation until A...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Masoud Toloue	President	2.5yrs	US$5.44m	0.53% $ 2.5m
David Walt	Co-Founder	17.8yrs	US$247.25k	3.87% $ 18.6m
Vandana Sriram	CFO & Treasurer	1.2yrs	US$1.35m	0.0063% $ 30.2k
Michael Miller	Chief Operating Officer	less than a year	Veri yok	Veri yok
Alexandra Phillips	Senior VP & Chief Information Officer	no data	Veri yok	Veri yok
Laurie Churchill	Senior VP	1.7yrs	Veri yok	Veri yok
Naren Bhat	Senior Vice President of Corporate Development & Strategy	1.2yrs	Veri yok	Veri yok
Erica Bell	Chief People Officer	2.8yrs	Veri yok	Veri yok
Mark Roskey	Chief Science & Collaboration Officer	10.1yrs	US$1.28m	Veri yok
Darrin Crisitello	Senior VP & Chief Commercial Officer	3.8yrs	Veri yok	Veri yok

2.5yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: QTRX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Masoud Toloue	President	2.5yrs	US$5.44m	0.53% $ 2.5m
David Walt	Co-Founder	17.5yrs	US$247.25k	3.87% $ 18.6m
Paul Meister	Independent Director	11.1yrs	US$259.96k	0.76% $ 3.6m
William P. Donnelly	Independent Director	1.2yrs	US$418.58k	0.058% $ 280.0k
Martin Madaus	Independent Chairman	13.9yrs	US$275.00k	0.73% $ 3.5m
Robert Corn	Member of Scientific Advisory Board	15.9yrs	Veri yok	Veri yok
Sarah Elizabeth McConnell	Independent Director	5.3yrs	US$259.96k	0.11% $ 523.2k
John Ramsey	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Larry Kricka	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jeffrey Elliott	Director	less than a year	Veri yok	Veri yok
Karen Flynn	Independent Director	2.3yrs	US$251.63k	0.038% $ 183.0k

5.3yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: QTRX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).

Quanterix Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Quanterix Corporation Appoints Ivana Magovcevic-Liebisch to Board of Directors

Quanterix Corporation Appoints Jeffrey Elliott to Its Board of Directors

Quanterix Corporation, Annual General Meeting, Jun 03, 2024

Quanterix Corporation Announces Laurie Olson, Director Will Not Stand for Re-Election

Director recently bought US$502k worth of stock

High number of new directors

Recent updates

Quanterix Corporation Appoints Ivana Magovcevic-Liebisch to Board of Directors

Quanterix Corporation Announces Commercialization of P-Tau 217 Test Kit

Quanterix Corporation: Still Struggling To Gain Traction

Quanterix Corporation Appoints Jeffrey Elliott to Its Board of Directors

Take Care Before Jumping Onto Quanterix Corporation (NASDAQ:QTRX) Even Though It's 26% Cheaper

Quanterix Corporation Revises Revenue Guidance for the Full-Year 2024

Quanterix Corporation to Report Q2, 2024 Results on Aug 08, 2024

Quanterix Corporation Presents Data Demonstrating Successful Multi-Marker Approach for Alzheimer’s Disease Detection that is More Effective than Standalone Plasma p-Tau 217

Positive Sentiment Still Eludes Quanterix Corporation (NASDAQ:QTRX) Following 25% Share Price Slump

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Quanterix Corporation Provides Earnings Guidance for the Full-Year 2024

Quanterix Corporation to Report Q1, 2024 Results on May 07, 2024

Price target decreased by 9.7% to US$29.80

New minor risk - Shareholder dilution

Quanterix Corporation, Annual General Meeting, Jun 03, 2024

Quanterix Corporation's (NASDAQ:QTRX) 31% Cheaper Price Remains In Tune With Revenues

Quanterix Corporation Announces Laurie Olson, Director Will Not Stand for Re-Election

Quanterix (NASDAQ:QTRX) Is In A Strong Position To Grow Its Business

Quanterix Corporation Receives Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease

Quanterix Corporation (NASDAQ:QTRX) Yearly Results: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings: EPS misses analyst expectations

Quanterix Corporation Provides Earnings Guidance for the Year 2024

Quanterix Corporation Reaffirms Earnings Guidance for the Year 2023

Quanterix Corporation to Report Q4, 2023 Results on Feb 27, 2024

Price target increased by 11% to US$33.25

New minor risk - Shareholder dilution

Quanterix Corporation Revises Earnings Guidance for the 2023

Quanterix Corporation Revises Earnings Guidance for the 2023

New major risk - Revenue and earnings growth

Quanterix Corporation to Report Q3, 2023 Results on Nov 06, 2023

Quanterix Launches High Accuracy P-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer's Disease

Here's Why We're Not Too Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Situation

Price target increased by 9.7% to US$31.00

Director recently bought US$502k worth of stock

High number of new directors

Quanterix Corporation Appoints William (Bill) P. Donnelly to its Board of Directors

Consensus estimates of losses per share improve by 20%

Quanterix Corporation Announces Michael Doyle Cease Serving as Treasurer, Effective August 21, 2023

Quanterix Corporation Provides Earnings Guidance for the Full-Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Quanterix Corporation to Report Q2, 2023 Results on Aug 08, 2023

Quanterix Corporation Launches LucentAD Biomarker Blood Test to Aid Physician Diagnosis of Alzheimer's Disease in Patients

We're Not Very Worried About Quanterix's (NASDAQ:QTRX) Cash Burn Rate

Consensus estimates of losses per share improve by 12%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 11% to US$15.25

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Quanterix (NASDAQ:QTRX) Can Afford To Drive Business Growth

Quanterix Corporation Appoints Brian Blaser to Board of Directors

Quanterix Corporation Simoa Technology Drives Advances in Alzheimer’s Disease Research Presented at 2022 Clinical Trials on Alzheimer’s Disease Conference

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Quanterix Corporation Reports Goodwill Impairment for the Third Quarter Ended September 30, 2022

Quanterix Corporation to Report Q3, 2022 Results on Nov 08, 2022

Quanterix Corporation: Selling For Less Than Cash Value

We Think Quanterix (NASDAQ:QTRX) Can Afford To Drive Business Growth

Quanterix Corporation Appoints Daniel Pikora as Chief Operating Officer

Quanterix stock gains after insider buys reported by CEO and CFO

Consensus forecasts updated

Independent Director recently bought US$2.0m worth of stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Quanterix Corporation Announces the Resignation of Kevin Hrusovsky as Executive Chairman of Board of Directors

Quanterix Corporation to Report Q2, 2022 Results on Aug 08, 2022

Price target decreased to US$34.50

Quanterix Corporation Launches First pTau-181 Plasma Laboratory Developed Test for Clinical Diagnostic and Research Applications in the U.S

Quanterix Corporation Announces Resignation of John Fry as General Counsel and Secretary, Effective August 12, 2022

President recently sold US$85k worth of stock

Quanterix Announces Appointment of Karen A. Flynn to Board of Directors

Quanterix Corporation Announces Resignation of Dawn Mattoon as Senior Vice President, Diagnostics, Effective July 10, 2022